著者
網岡 尚史 渡邊 敦之 大塚 寛昭 赤木 達 麻植 浩樹 中川 晃志 中村 一文 森田 宏 小谷 恭弘 新井 禎彦 笠原 真悟 佐野 俊二 伊藤 浩
出版者
公益財団法人 日本心臓財団
雑誌
心臓 (ISSN:05864488)
巻号頁・発行日
vol.49, no.SUPPL.1, pp.S1_110, 2017-08-28 (Released:2018-08-28)

症例は17歳男性.4年前より運動時に胸痛,失神を認め,症状は増悪傾向であった.他院にて電気生理学的検査まで含めた諸検査を施行するも原因不明であり当院に紹介,入院精査となった.入院時に施行したトレッドミル負荷試験にて心電図上,aVRにST上昇が出現,補充調律に移行,また著明な血圧低下,胸部絞扼感,前失神症状を呈した.冠動脈の器質的異常を疑い冠動脈CTおよびCAGを施行したところ左冠動脈は右冠尖起始であり,主幹部は大動脈と肺動脈に挟まれ圧迫,変形していた.失神の原因は左冠動脈圧排による虚血と診断し心臓血管外科に紹介,手術加療の方針となった.冠動脈起始異常は臨床上,しばしば認められる先天的異常であるが,若年者の突然死の原因ともなり得る.若年者における繰り返す失神の一因として冠動脈起始異常は考慮すべきと考えられ,啓蒙的に報告する.
著者
石神 修大 佐野 俊二 王 英正
出版者
一般社団法人 日本移植学会
雑誌
移植 (ISSN:05787947)
巻号頁・発行日
vol.50, no.6, pp.565-575, 2015-12-10 (Released:2015-12-20)
参考文献数
47

In July 2010, the domestic law for organ transplants was revised to enable children under 15-year of age to donate their organs if the parents had given consent in the case of brain death. After this revision, the substantial number of pediatric heart transplantations was expected to increase; however only 7 cases were performed during these 5 years. The problems related to the shortage of organ donors and long waiting times for orthotopic heart transplantations have not yet been resolved. As a result, new treatment strategies including innovative mechanical devices and regenerative therapies for pediatric heart failure, are critically needed. Accumulated evidence of cardiac regeneration strategies using various types of somatic stem cells have revealed the efficacy of stem cell therapies for heart failure. Initial results of the Transcoronary Infusion of Cardiac Progenitor cell infusion in patients with single ventricle physiology (TICAP) phase I study (NCT01273857) conducted at Okayama University (2011-2013) have shown that intracoronary infusion of cardiosphere-derived cells (CDCs) following staged palliation was feasible and safe to treat children with hypoplastic left heart syndrome. Currently, a randomized phase II trial (Cardiac Progenitor Cell Infusion to treat Univentricular Heart Disease: PERSEUS, NCT01829750) is ongoing at our institution to verify the therapeutic efficacy of CDC infusion in patients with univentricular heart diseases. From 2016, we will conduct a countrywide sponsor-initiated multicenter clinical trial to construct this therapeutic strategy for children with heart failure as an insurance coverage treatment. In this review, we discuss the problems involved with end-stage pediatric heart failure and the current status of stem cell therapy for heart failure in children.